1,135 results match your criteria Prostate Cancer - Management of Localized Disease


Metastasis-free survival as a new endpoint in castration- -resistant prostate cancer.

Authors:
M Kuzma J Kliment

Bratisl Lek Listy 2020 ;121(6):411-414

Introduction: Recent breakthrough recognition of metastasis-free survival as a clinically relevant endpoint has opened a new era in the management of advanced prostate cancer. The need for new, intermediate endpoints is the logical consequence of scientific advances in prostate carcinoma. The treatment algorithms for non-metastatic castration-resistant prostate cancer (M0 CRPC) have recently been updated by adding novel anti-androgen apalutamide, and also enzalutamide for high-risk patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4149/BLL_2020_066DOI Listing
January 2020

Magnetic resonance imaging of the prostate after focal therapy with high-intensity focused ultrasound.

Abdom Radiol (NY) 2020 May 23. Epub 2020 May 23.

Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, 10065, USA.

For clinically significant, locally confined prostate cancer, whole-gland radical prostatectomy and radiotherapy are established effective treatment strategies that, however, come at a cost of significant morbidity related to urinary and sexual side effects. The concept of risk stratification paired with a better understanding of prognostic factors has led to the development of alternative management options including active surveillance and focal therapy for appropriately selected patients with localized disease. High-intensity focused ultrasound (HIFU) is one such minimally invasive, image-guided treatment option for prostate cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00261-020-02577-5DOI Listing

Imaging and Management of Prostate Cancer.

Semin Ultrasound CT MR 2020 Apr 18;41(2):207-221. Epub 2020 Feb 18.

Department of Abdominal Imaging, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX.

Prostate cancer (PCa) is the most common noncutaneous malignancy in men and the second leading cause of cancer related death in the United States. Men with clinical suspicion of PCa undergo tissue sampling and based on features including the Gleason score, Prostate Specific antigen (PSA) levels and clinical tumor (T) stage, patients are risk stratified into 6 major groups based on National Comprehensive Cancer Network (NCCN) guidelines. This forms the basis for deciding imaging and management. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.sult.2020.02.001DOI Listing

Techniques of robotic radical prostatectomy for the management of prostate cancer: which one, when and why.

Transl Androl Urol 2020 Apr;9(2):906-918

Department of Urology, Wake Forest Baptist Health, Winston-Salem, North Carolina, USA.

The advent of robotic assistance in surgery has completely revolutionized the surgical management of prostate cancer. It enables precise dissection and reconstruction in order to maximize oncological and functional outcomes. In many parts of the world, robot-assisted laparoscopic radical prostatectomy has evolved to become the surgical standard of care for localized disease, including in appropriately selected patients with high risk prostate cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/tau.2019.09.13DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214982PMC

Recent Advances in the Management of High-Risk Localized Prostate Cancer: Local Therapy, Systemic Therapy, and Biomarkers to Guide Treatment Decisions.

Am Soc Clin Oncol Educ Book 2020 May;40:1-12

Vanderbilt University Medical Center, Nashville, TN.

High-risk prostate cancer accounts for approximately 15% of all prostate cancer diagnoses. Patients with high-risk disease have an increased risk of developing biochemical recurrence, metastases, and death from prostate cancer. As the optimal management of high-risk disease in patients with prostate cancer continues to evolve, the contemporary treatment paradigm is moving toward a multidisciplinary integrated approach of systemic and local therapy for patients with high-risk disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_279459DOI Listing

Prostate Cancer Radiotherapy Recommendations in Response to COVID-19.

Adv Radiat Oncol 2020 Apr 1. Epub 2020 Apr 1.

Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan, USA.

Purpose: During a global pandemic the benefit of routine visits and treatment of cancer patients must be weighed against the risks to patients, staff, and society. Prostate cancer is one of the most common cancers Radiation Oncology departments treat, and efficient resource utilization is essential in the setting of a pandemic. Herein, we aim to establish recommendations and a framework by which to evaluate prostate radiotherapy management decisions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.adro.2020.03.010DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7118610PMC

Genetic Variants in Epithelial Mesenchymal Transition Genes as Predictors of Clinical Outcomes in Localized Prostate Cancer.

Carcinogenesis 2020 Mar 26. Epub 2020 Mar 26.

Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Background: Epithelial mesenchymal transition (EMT) plays a pivotal role in the progression of prostate cancer (PCa). However, little is known about genetic variants in the EMT pathway as predictors of aggressiveness, biochemical recurrence (BCR), and disease reclassification in localized PCa.

Patients And Methods: In this multi-stage study, we evaluated 5,186 single nucleotide polymorphisms (SNPs) from 264 genes related to EMT pathway to identify SNPs associated with PCa aggressiveness and BCR in the MD Anderson PCa patient (MDA-PCa) cohort (N=1,762), followed by assessment of the identified SNPs with disease reclassification in the active surveillance (AS) cohort (N=392). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/carcin/bgaa026DOI Listing

Utilizing Digital Health to Collect Electronic Patient-Reported Outcomes in Prostate Cancer: Single-Arm Pilot Trial.

J Med Internet Res 2020 Mar 25;22(3):e12689. Epub 2020 Mar 25.

H Lee Moffitt Cancer Center, Department of Health Outcomes and Behavior, Tampa, FL, United States.

Background: Measuring patient-reported outcomes (PROs) requires an individual's perspective on their symptoms, functional status, and quality of life. Digital health enables remote electronic PRO (ePRO) assessments as a clinical decision support tool to facilitate meaningful provider interactions and personalized treatment.

Objective: This study explored the feasibility and acceptability of collecting ePROs using validated health-related quality of life (HRQoL) questionnaires for prostate cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2196/12689DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7142743PMC

Androgen deprivation therapy: indications, methods of utilization, side effects and their management.

Can J Urol 2020 Feb;27(1S1):11-16

Division of Urology, Department of Surgery, University of Toronto, Toronto, Ontario, Canada.

Our objective is to provide an up-to-date summary of current literature on the indications for androgen deprivation therapy (ADT), ways in which ADT is used, and the main side effects associated with its use. MEDLINE (Pubmed) was searched for relevant papers published from database inception to May 1, 2019 for studies evaluating the use of ADT and its associated adverse events. ADT is a mainstay in the treatment of prostate cancer and is used throughout the disease course. Read More

View Article

Download full-text PDF

Source
February 2020

Focal therapy for localized prostate cancer in the era of routine multi-parametric MRI.

Prostate Cancer Prostatic Dis 2020 Jun 12;23(2):232-243. Epub 2020 Feb 12.

Royal Surrey NHS Foundation Trust, Guildford, Surrey, GU2 7XX, UK.

Background: Prostate cancer focal therapy aims to minimize the side-effects of whole gland treatments, such as radical prostatectomy and radiotherapy without compromising oncological efficacy. However, concerns exist regarding the multifocal nature of prostate cancer and the lack of long-term oncological data for this form of treatment. In recent years, the routine adoption of multi-parametric magnetic resonance imaging (mpMRI) of the prostate has improved our ability to select candidates for focal therapy and to accurately deliver this form of prostate cancer treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41391-020-0206-6DOI Listing
June 2020
3.425 Impact Factor

Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers. I. Molecular Biomarkers in Prostate Cancer.

Am J Surg Pathol 2020 Jul;44(7):e15-e29

Institute of Pathology, University Hospital Basel, Basel, Switzerland.

The combined clinical and molecular heterogeneity of prostate cancer necessitates the use of prognostic, predictive, and diagnostic biomarkers to assist the clinician with treatment selection. The pathologist plays a critical role in guiding molecular biomarker testing in prostate cancer and requires a thorough knowledge of the current testing options. In the setting of clinically localized prostate cancer, prognostic biomarkers such as Ki-67 labeling, PTEN loss or mRNA-based genomic signatures can be useful to help determine whether definitive therapy is required. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAS.0000000000001450DOI Listing
July 2020
5.145 Impact Factor

[Noninvasive treatment of organ-confined prostate cancer in elderly patients-results of the HAROW study].

Urologe A 2020 Apr;59(4):450-460

Gesundheitsforschung für Männer gGmbH, Berlin, Deutschland.

Background: Noninvasive treatment options such as active surveillance (AS), watchful waiting (WW), and hormone deprivation therapy (HT) are particularly important in elderly patients with localized prostate cancer (PCa).

Objectives: We examine the use of these noninvasive treatment options in the everyday care in a cohort of patients ≥70 years old.

Materials And Methods: In the HAROW study, the treatment of localized PCa under everyday conditions is investigated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00120-020-01123-xDOI Listing

Targeting MEK5 impairs nonhomologous end-joining repair and sensitizes prostate cancer to DNA damaging agents.

Oncogene 2020 Mar 24;39(12):2467-2477. Epub 2020 Jan 24.

Center for Radiological Research, Columbia University Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, USA.

Radiotherapy is commonly used to treat a variety of solid human tumors, including localized prostate cancer. However, treatment failure often ensues due to tumor intrinsic or acquired radioresistance. Here we find that the MEK5/ERK5 signaling pathway is associated with resistance to genotoxic stress in aggressive prostate cancer cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41388-020-1163-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7085449PMC
March 2020
8.459 Impact Factor

Next Generation of Androgen Deprivation Therapy Combined With Radiotherapy for N0 M0 Prostate Cancer.

Cancer J 2020 Jan/Feb;26(1):21-28

From the Department of Hematology and Medical Oncology.

Androgen deprivation therapy in combination with definitive radiation therapy is a standard of care for both intermediate-/high-risk localized prostate, locally advanced prostate cancer. Newer hormonal therapies have shown promising results in patients with castration-resistant disease and are now being investigated in early stages, in combination with radiation therapy. In this section, we review the body of evidence elucidating the mechanism of synergy and immune modulation effect of androgen deprivation therapy and radiation therapy, summarize the pivotal studies supporting its use in the nonmetastatic setting, and present the ongoing studies who will likely shape the management of locally advanced disease, in the upcoming years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0000000000000428DOI Listing
January 2020

Physician and facility drivers of spending variation in locoregional prostate cancer.

Cancer 2020 Apr 24;126(8):1622-1631. Epub 2020 Jan 24.

Department of Health Policy and Management, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.

Background: Prostate cancer is the most common male cancer, with a wide range of treatment options. Payment reform to reduce unnecessary spending variation is an important strategy for reducing waste, but its magnitude and drivers within prostate cancer are unknown.

Methods: In total, 38,971 men aged ≥66 years with localized prostate cancer who were enrolled in Medicare fee-for-service and were included in the Surveillance, Epidemiology, and End Results-Medicare database from 2009 to 2014 were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.32719DOI Listing

Expanding the role of small-molecule PSMA ligands beyond PET staging of prostate cancer.

Nat Rev Urol 2020 02 14;17(2):107-118. Epub 2020 Jan 14.

Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.

Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) is rapidly being established as arguably the leading contemporary imaging modality in the management of prostate cancer. Outside of its conventional use in the de novo staging of localized disease and detection of biochemical recurrence, additional applications for the use of PSMA PET are emerging. Uptake of PSMA tracers in other genitourinary malignancies, particularly renal cell carcinoma, has led to new fields of investigation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41585-019-0272-5DOI Listing
February 2020

Tumour innervation and neurosignalling in prostate cancer.

Nat Rev Urol 2020 02 14;17(2):119-130. Epub 2020 Jan 14.

Hunter Medical Research Institute, University of Newcastle, New Lambton, NSW, Australia.

Prostate cancer progression has been shown to be dependent on the development of autonomic nerves into the tumour microenvironment. Sympathetic nerves activate adrenergic neurosignalling that is necessary in early stages of tumour progression and for initiating an angiogenic switch, whereas parasympathetic nerves activate cholinergic neurosignalling resulting in tumour dissemination and metastasis. The innervation of prostate cancer seems to be initiated by neurotrophic growth factors, such as the precursor to nerve growth factor secreted by tumour cells, and the contribution of brain-derived neural progenitor cells has also been reported. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41585-019-0274-3DOI Listing
February 2020

Patient-Reported Outcomes Through 5 Years for Active Surveillance, Surgery, Brachytherapy, or External Beam Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer.

JAMA 2020 01;323(2):149-163

Department of Urology, Vanderbilt University Medical Center, Nashville, Tennessee.

Importance: Understanding adverse effects of contemporary treatment approaches for men with favorable-risk and unfavorable-risk localized prostate cancer could inform treatment selection.

Objective: To compare functional outcomes associated with prostate cancer treatments over 5 years after treatment.

Design, Setting, And Participants: Prospective, population-based cohort study of 1386 men with favorable-risk (clinical stage cT1 to cT2bN0M0, prostate-specific antigen [PSA] ≤20 ng/mL, and Grade Group 1-2) prostate cancer and 619 men with unfavorable-risk (clinical stage cT2cN0M0, PSA of 20-50 ng/mL, or Grade Group 3-5) prostate cancer diagnosed in 2011 through 2012, accrued from 5 Surveillance, Epidemiology and End Results Program sites and a US prostate cancer registry, with surveys through September 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jama.2019.20675DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6990712PMC
January 2020

Tumor burden and location as prognostic factors in patients treated by iodine seed implant brachytherapy for localized prostate cancers.

Radiat Oncol 2019 Dec 31;15(1). Epub 2019 Dec 31.

Hôpital Européen Georges Pompidou, 20 rue Leblanc, 75015, Paris, France.

Background: Iodine seed implant brachytherapy is indicated for low risk and selected favorable intermediate risk prostate cancers. A percentage of positive biopsies > 50% is usually considered as a contra-indication, and the tumor location could also influence the treatment efficacy. We studied the association of the percentage of positive biopsy cores, and tumor location, with progression-free survival. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13014-019-1449-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6938614PMC
December 2019

Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline.

J Clin Oncol 2020 May 12;38(13):1474-1494. Epub 2019 Dec 12.

Dana-Farber Cancer Institute, Boston, MA.

Purpose: This guideline provides recommendations for available tissue-based prostate cancer biomarkers geared toward patient selection for active surveillance, identification of clinically significant disease, choice of postprostatectomy adjuvant versus salvage radiotherapy, and to address emerging questions such as the relative value of tissue biomarkers compared with magnetic resonance imaging.

Methods: An ASCO multidisciplinary Expert Panel, with representatives from the European Association of Urology, American Urological Association, and the College of American Pathologists, conducted a systematic literature review of localized prostate cancer biomarker studies between January 2013 and January 2019. Numerous tissue-based molecular biomarkers were evaluated for their prognostic capabilities and potential for improving management decisions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.19.02768DOI Listing
May 2020
5 Reads
18.428 Impact Factor

Associations of low-dose aspirin or other NSAID use with prostate cancer risk in the Danish Diet, Cancer and Health Study.

Cancer Causes Control 2020 Feb 10;31(2):139-151. Epub 2019 Dec 10.

Danish Cancer Society Research Center, Danish Cancer Society, Strandboulevarden 49, 2100, Copenhagen Ø, Denmark.

Purpose: Epidemiologic studies suggest that use of aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) may reduce prostate cancer risk. We examined these associations overall and according to clinical and lifestyle parameters.

Methods: We identified male participants in the Danish Diet, Cancer and Health Study (n = 26,339), holding information on anthropometric measures and lifestyle factors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10552-019-01252-5DOI Listing
February 2020

Intensity modulated radiotherapy (IMRT) or conformational radiotherapy (3D-CRT) with conventional fractionation for prostate cancer: Is there any clinical difference?

Int Braz J Urol 2019 Nov-Dec;45(6):1105-1112

Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo - USP, Ribeirão Preto, SP, Brasil.

Purpose: To compare the treatment outcomes of a cohort of prostate cancer patients treated with conventional schedule using IMRT or 3DRT technique.

Materials And Methods: Between 2010-2017, 485 men with localized prostate cancer were treated with conventional radiotherapy schedule with a total dose ≥74Gy using IMRT (231) or 3DCRT (254). Late gastrointestinal (GI) and genitourinary (GU) toxicity were retrospectively evaluated according to modifi ed RTOG criteria. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1590/S1677-5538.IBJU.2018.0842DOI Listing
January 2020

Therapeutic options in patients with biochemical recurrence after radical prostatectomy.

Exp Ther Med 2019 Dec 20;18(6):5021-5025. Epub 2019 Aug 20.

University of Medicine and Pharmacy Carol Davila, 050474 Bucharest, Romania.

Prostate cancer is the second most common form of cancer in men in Europe. The primary treatment of this type of cancer is radical prostatectomy, which has shown good oncological results. Radical prostatectomy (open, laparoscopic or robotic) has high success and low morbidity rates in patients with localized prostate cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/etm.2019.7916DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6880385PMC
December 2019

Magnetic Resonance-Guided Prostate Ablation.

Semin Intervent Radiol 2019 Dec 2;36(5):351-366. Epub 2019 Dec 2.

Department of Urology, Mayo Clinic, Rochester, Minnesota.

In 2019, the American Cancer Society (ACS) estimates that 174,650 new cases of prostate cancer will be diagnosed and 31,620 will die due to the prostate cancer in the United States. Prostate cancer is often managed with aggressive curative intent standard therapies including radiotherapy or surgery. Regardless of how expertly done, these standard therapies often bring significant risk and morbidity to the patient's quality of life with potential impact on sexual, urinary, and bowel functions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/s-0039-1697001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6887527PMC
December 2019

A Limited-Versus-Extensive Staging Strategy for Small Cell Prostate Cancer.

Am J Clin Oncol 2020 02;43(2):87-93

Departments of Internal Medicine.

Introduction: Small cell prostate cancer (SCPC) is a rare histologic subtype of prostate cancer, for which the optimal staging strategy remains unclear.

Method: The Surveillance, Epidemiology, and End Results database was used to analyze the incidence and outcomes of SCPC between the years 2004 through 2016. Limited-stage SCPC (LS-SCPC) was defined as SCPC without any metastasis regardless of local invasion. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000631DOI Listing
February 2020
2.611 Impact Factor

Local Failure and Survival After Definitive Radiotherapy for Aggressive Prostate Cancer: An Individual Patient-level Meta-analysis of Six Randomized Trials.

Eur Urol 2020 Feb 10;77(2):201-208. Epub 2019 Nov 10.

Department of Radiation Oncology, Cedars Sinai, Los Angeles, CA, USA.

Background: The importance of local failure (LF) after treatment of high-grade prostate cancer (PCa) with definitive radiotherapy (RT) remains unknown.

Objective: To evaluate the clinical implications of LF after definitive RT.

Design, Setting, And Participants: Individual patient data meta-analysis of 992 patients (593 Gleason grade group [GG] 4 and 399 GG 5) enrolled in six randomized clinical trials. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2019.10.008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7008470PMC
February 2020
5 Reads

Clinical Utility of the Nuclear-localized AR-V7 Biomarker in Circulating Tumor Cells in Improving Physician Treatment Choice in Castration-resistant Prostate Cancer.

Eur Urol 2020 Feb 21;77(2):170-177. Epub 2019 Oct 21.

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA. Electronic address:

Background: Proof of the clinical utility of a biomarker is when its use informs a management decision and improves patient outcomes relative to when it is not used.

Objective: To model the clinical benefit of the nuclear-localized androgen receptor splice variant 7 (AR-V7) test for men with progressing metastatic castration-resistant prostate cancer (mCRPC) at the second line of therapy or greater to inform the choice of an androgen receptor signaling inhibitor (ARSI) or a taxane.

Design, Setting, And Participants: The study population was a cross-sectional cohort of 193 unique patients with progressing mCRPC from whom 255 samples were drawn at the time of the second line or later treatment decision who then received an ARSI or taxane, with up to 3 yr of additional follow-up Circulating tumor cells (CTCs) were identified from blood samples and tested for AR-V7. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2019.08.020DOI Listing
February 2020

A Review of Localized Prostate Cancer: An African Perspective.

World J Oncol 2019 Oct 20;10(4-5):162-168. Epub 2019 Sep 20.

Department of Urology and Andrology, Hopital General de Grand Yoff, Dakar, Senegal.

Prostate cancer is the second most common malignancy in males and the sixth leading cause of cancer mortality in men with a relatively higher death rate in men of African descent. In the United States and other parts of Europe, more than 80% of diagnosed prostate cancer is localized, and 80-90% of these men receive some form of treatment. The projected data may not be a direct reflection of the disease in the sub-Saharan region as less than 40% presents with localized disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14740/wjon1221DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6785274PMC
October 2019
1 Read

Prospective Evaluation of F-DCFPyL PET/CT in Biochemically Recurrent Prostate Cancer in an Academic Center: A Focus on Disease Localization and Changes in Management.

J Nucl Med 2020 Apr 18;61(4):546-551. Epub 2019 Oct 18.

Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Stanford University, Stanford, California

F-DCFPyL (2-(3-{1-carboxy-5-[(6-F-fluoropyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid) is a promising PET radiopharmaceutical targeting prostate-specific membrane antigen (PSMA). We present our experience with this single-academic-center prospective study evaluating the positivity rate of F-DCFPyL PET/CT in patients with biochemical recurrence (BCR) of prostate cancer (PC). We prospectively enrolled 72 men (52-91 y old; mean ± SD, 71. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.119.231654DOI Listing
April 2020
1 Read

[French ccAFU guidelines - Update 2018-2020: Prostate cancer].

Prog Urol 2018 11 23;28 Suppl 1:R81-R132. Epub 2019 Aug 23.

Comité de cancérologie de l'Association française d'urologie, groupe prostate, maison de l'urologie, 11, rue Viète, 75017 Paris, France; Service d'urologie, hôpital européen Georges-Pompidou, université Paris Descartes, Assistance publique des hôpitaux de Paris (AP-HP), 75015 Paris, France.

Objective: The purpose of the guidelines national committee ccAFU was to propose updated French guidelines for prostate cancer.

Methods: A Medline search was achieved between 2016 and 2018, as regards diagnosis, options of treatment and follow-up of prostate cancer, and to evaluate the different references specifying their levels of evidence.

Results: Epidemiology, classification, staging systems, diagnostic evaluation of prostate cancer are reported. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.purol.2019.01.007DOI Listing
November 2018
3 Reads

Stereotactic body radiation therapy for prostate cancer: systematic review and meta-analysis of prospective trials.

Oncotarget 2019 09 24;10(54):5660-5668. Epub 2019 Sep 24.

Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD, USA.

Despite the increasing worldwide utilization of stereotactic body radiation therapy (SBRT) for prostate cancer, there are no known summative data regarding its safety and efficacy. To address this knowledge gap, we conducted a PRISMA-guided systematic review and meta-analysis of prospective prostate SBRT trials. Fourteen trials with a total of 2,038 patients were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.27177DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6771455PMC
September 2019
2 Reads

Tissue-based genomics: which test and when.

Curr Opin Urol 2019 11;29(6):598-604

Department of Urology.

Purpose Of Review: The clinical course of localized prostate cancer varies widely, ranging from indolent disease unlikely to require treatment to aggressive cancers meriting intensive, multimodal therapy. Management recommendations have traditionally been determined based on clinical and pathologic factors, including serum prostate - specific antigen (PSA), clinical stage, and Gleason score. Unfortunately, these factors have limited ability to describe the underlying biology of a given tumor. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOU.0000000000000673DOI Listing
November 2019
2 Reads

Risk stratification and avoiding overtreatment in localized prostate cancer.

Curr Opin Urol 2019 11;29(6):612-619

Urology Unit, Department of Surgery, University of Melbourne, Austin Hospital.

Purpose Of Review: Significant morbidity is associated with overtreatment of clinically localized prostate cancer (PCa). Risk stratification tools such as novel biomarkers, MRI and risk calculators are useful in predicting which patients would benefit from active surveillance. This review examines current risk stratification tools in localized PCa and the safety of active surveillance in these patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOU.0000000000000672DOI Listing
November 2019
2.333 Impact Factor

Quality of Life-Focused Decision-Making for Prostate Cancer.

Curr Urol Rep 2019 Aug 29;20(10):57. Epub 2019 Aug 29.

Division of Hematology and Oncology, Department of Medicine, Northwestern University, 676 N. St. Clair, Suite 850, Chicago, IL, 60611, USA.

Purpose Of Review: Quality of life (QoL) outcomes have been reported in the literature and incorporated in decision-making in localized prostate cancer management for decades. Until recently, there was less emphasis on understanding the QoL effects of therapies for patients with advanced disease, possibly because there were fewer options for treatment. The purpose of this review is to summarize the key recent literature describing QoL outcomes for prostate cancer treatments in different disease settings. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11934-019-0924-2DOI Listing
August 2019
2 Reads

Active surveillance for intermediate-risk prostate cancer: yes, but for whom?

Curr Opin Urol 2019 11;29(6):605-611

Department of Urology.

Purpose Of Review: Active surveillance is becoming more widely accepted as an initial management option for carefully selected men with favorable intermediate-risk prostate cancer (PCa). As prospective active surveillance cohorts mature sufficiently to begin evaluating longer-term outcomes, consensus on more precise evidence-based guidelines is needed to identify the patient cohorts who may be safely managed with active surveillance and what the ideal surveillance protocol entails.

Recent Findings: Long-term outcomes updates have suggested a trend toward worse 15-year survival outcomes for intermediate-risk patients on active surveillance compared with definitive treatment, but 'intermediate-risk' is a broad category and there is a subset of favorable intermediate-risk patients for whom survival outcomes remain equivalent. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOU.0000000000000671DOI Listing
November 2019

Under Treatment of Prostate Cancer in Rural Locations.

J Urol 2020 01 20;203(1):108-114. Epub 2019 Aug 20.

Departments of Urology, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania.

Purpose: Compared to urban populations, rural populations rank poorly on numerous health indicators, including cancer outcomes. We examined the relationship of rural residence with stage and treatment among patients with prostate cancer, the second most common malignancy in men.

Materials And Methods: Using the Pennsylvania Cancer Registry we identified all men diagnosed with prostate cancer between 2009 and 2015. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JU.0000000000000500DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7098431PMC
January 2020
3 Reads
4.471 Impact Factor

Prediction of Recurrence-associated Death from Localized Prostate Cancer with a Charlson Comorbidity Index-reinforced Machine Learning Model.

Open Med (Wars) 2019 14;14:593-606. Epub 2019 Aug 14.

Graduate Institute of Business Administration, College of Management, Fu Jen Catholic University, New Taipei City 24205, Taiwan.

Research has failed to resolve the dilemma experienced by localized prostate cancer patients who must choose between radical prostatectomy (RP) and external beam radiotherapy (RT). Because the Charlson Comorbidity Index (CCI) is a measurable factor that affects survival events, this research seeks to validate the potential of the CCI to improve the accuracy of various prediction models. Thus, we employed the Cox proportional hazard model and machine learning methods, including random forest (RF) and support vector machine (SVM), to model the data of medical records in the National Health Insurance Research Database (NHIRD). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1515/med-2019-0067DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6698054PMC
August 2019
1 Read

Practice Patterns and Outcomes Among Patients With N0M0 Prostate Cancer and a Very High Prostate-Specific Antigen Level.

J Natl Compr Canc Netw 2019 08;17(8):941-948

Department of Radiation Oncology, Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, Massachusetts.

Background: Management of patients with a very high prostate-specific antigen (PSA) level (≥98.0 ng/mL) but clinically localized (N0M0) prostate cancer is challenging. This study sought to determine practice patterns and outcomes among these patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2018.7283DOI Listing
August 2019
3 Reads

Management algorithms for prostate-specific antigen progression in prostate cancer: Biochemical recurrence after definitive therapy and progression to non-metastatic castrate-resistant prostate cancer.

Can Urol Assoc J 2019 Dec 7;13(12):420-426. Epub 2019 Feb 7.

Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada.

Introduction: Current prostate cancer (PCa) guidelines primarily focus on localized or metastatic PCa. A multidisciplinary genitourinary oncology panel determined that additional guidance focusing on monitoring and management of biochemical recurrence (BCR) following radical therapy and non-metastatic castration-resistant prostate cancer (nmCRPC) was warranted.

Methods: The most up-to-date national and international guidelines, consensus statements, and emerging phase 3 trials were identified and used to inform development of algorithms by a multidisciplinary genitourinary oncology panel outlining optimal monitoring and treatment for patients with non-metastatic PCa. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5489/cuaj.5600DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6892682PMC
December 2019
1 Read

Establishment of the Seoul National University Prospectively Enrolled Registry for Genitourinary Cancer (SUPER-GUC): A prospective, multidisciplinary, bio-bank linked cohort and research platform.

Investig Clin Urol 2019 07 20;60(4):235-243. Epub 2019 May 20.

Department of Urology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.

Purpose: To establish a prospective, comprehensive, multidisciplinary, bio-bank linked genitourinary cancer cohort based on standard real practice.

Materials And Methods: We established the Seoul National University Prospectively Enrolled Registry for Genitourinary Cancer (SUPER-GUC), a prospective cohort clinical database and bio-specimen repository system for prostate cancer (SUPER-PC), renal cell carcinoma (SUPER-RCC), and urothelial cancer (SUPER-UC) at a high-volume, tertiary institution. Each cohort consists of several sub-cohorts based on treatment or disease status. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4111/icu.2019.60.4.235DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6607078PMC
July 2019
4 Reads

Importance of the correct assessment of bone fractures in the clinical management of metastatic castration-resistant prostate cancer treated with radium-223: A case report.

Mol Clin Oncol 2019 Jul 6;11(1):63-66. Epub 2019 May 6.

Radiation Oncology Center, S. Orsola-Malpighi Hospital, I-40138 Bologna, Italy.

Patients who undergo radium-223 treatment for metastatic castration-resistant prostate cancer (mCRPC) generally have a long history of androgen deprivation therapy and/or steroid therapy, which leads to bone loss and causes osteoporosis. Notably, Osteoporosis in combination with metastatic bone disease increases the risk of bone fracture. An 84-year-old man with multi-metastatic bone CRPC underwent six administrations of intravenous radium-223, which induced a good biochemical and clinical response. Read More

View Article

Download full-text PDF

Source
http://www.spandidos-publications.com/10.3892/mco.2019.1852
Publisher Site
http://dx.doi.org/10.3892/mco.2019.1852DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6535633PMC
July 2019
3 Reads

Effect of Immunotherapy on Local Treatment of Genitourinary Malignancies.

Eur Urol Oncol 2019 07 31;2(4):355-364. Epub 2019 Jan 31.

Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA.

Context: Management of metastatic genitourinary malignancies has recently been transformed through the use of immune checkpoint inhibitors. The best way to integrate them into local treatment paradigms is still under investigation.

Objective: To systematically evaluate evidence regarding the use of immunotherapy in the treatment of local disease, in both the perioperative and the metastatic setting. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euo.2019.01.002DOI Listing
July 2019
4 Reads

[Vascular targeted photodynamic therapy in low-risk prostate cancer. A literature review].

Prog Urol 2019 Jul - Aug;29(8-9):393-401. Epub 2019 Jun 29.

Service d'urologie, hopital universitaire d'Angers, 49933 Angers, France.

Introduction: Currently, about 50% of newly prostate cancers are localized and low-risk according to D'Amico risk classification. Focal therapies whose objective is to treat only the index lesion appear as a new alternative being evaluated in the management of these cancers. Besides the interest in the control of the disease, focal therapies present a very low risk of morbidity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.purol.2019.05.004DOI Listing
January 2020
6 Reads

[Diagnostic and therapeutic management in a series of 1156 patients with the diagnosis of prostate cancer in Castilla y Leon during 2014.]

Arch Esp Urol 2019 Jun;72(5):463-470

Complejo Asistencial Universitario de Salamanca y Grupo de Investigaciones Traslacionales en Urología (IBSALGITUR).

Objectives: To evaluate the current clinical practice for patients with Prostate Cancer (CP) in the Health Areas of Castilla y León (CyL) in 2014. METHODS: A retrospective multicenter study was designed to provide data on the diagnosis and treatment of PC in CyL: 87.8% of patients were screened. Read More

View Article

Download full-text PDF

Source
June 2019
23 Reads

Factors associated with trial recruitment, preferences, and treatments received were elucidated in a comprehensive cohort study.

J Clin Epidemiol 2019 09 3;113:200-213. Epub 2019 Jun 3.

Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.

Objectives: Recruitment to pragmatic trials is often difficult, and little is known about factors associated with key participation and treatment decisions. These were explored in the Prostate cancer testing and Treatment (ProtecT) study.

Study Design And Setting: Baseline sociodemographic, patient-reported outcome, clinical history, and prostate cancer biopsy data were collected for all patients eligible to take part in the ProtecT trial, in a comprehensive cohort design. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jclinepi.2019.05.036DOI Listing
September 2019
15 Reads

A review of salvage treatment options for disease progression after radiation therapy for localized prostate cancer.

Urol Oncol 2019 09 24;37(9):582-598. Epub 2019 May 24.

Department of Radiation Oncology, Indiana University School of Medicine, Indianapolis, IN; Indiana University Simon Cancer Center, Indianapolis, IN. Electronic address:

Recurrence of prostate cancer after initial treatment with radiation therapy (RT) is highly dependent on pretreatment risk group and unfortunately, a proportion of patients fail primary treatment. The treatment of recurrence after primary radiation is rapidly changing with advances in imaging and it is important to distinguish those with a local failure from those with distant failure. If disease remains locally confined, salvage treatment with a variety of techniques can still provide a potential cure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2019.04.030DOI Listing
September 2019
8 Reads

Healthcare providers' discussions of physical activity with older survivors of cancer: Potential missed opportunities for health promotion.

J Geriatr Oncol 2020 Apr 20;11(3):437-443. Epub 2019 May 20.

Outcomes Research Branch, National Cancer Institute, 9609 Medical Center Drive, Rockville, MD 20850, USA.

Objectives: Physical activity (PA) promotes physical functioning and health-related quality of life in older survivors of cancer. Using a population-based sample of Medicare Advantage beneficiaries, we aimed to characterize the survivors who reported discussing PA with their healthcare provider.

Materials And Methods: Data from the Surveillance, Epidemiology, and End Results (SEER) cancer registries was linked with the 2008-2014 Medicare Health Outcomes Survey (MHOS). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jgo.2019.05.007DOI Listing
April 2020
7 Reads

Two-year Outcomes Following Focal Laser Ablation of Localized Prostate Cancer.

Eur Urol Oncol 2018 06 15;1(2):129-133. Epub 2018 May 15.

Department of Urology, New York University School of Medicine, New York, NY, USA. Electronic address:

Background: There is no consensus regarding how to assess oncological control following focal ablation of prostate cancer.

Objective: To assess quality of life and in-field recurrence following focal laser ablation (FLA).

Design, Setting, And Participants: Of 34 men participating in a prospective outcomes study following FLA, 32 underwent prostate-specific antigen (PSA) testing and magnetic resonance imaging (MRI) at 6 mo and 2 yr. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euo.2018.03.011DOI Listing
June 2018
4 Reads

Oligometastatic Prostate Cancer: A Shrinking Subset or an Opportunity for Cure?

Am Soc Clin Oncol Educ Book 2019 Jan 17;39:309-320. Epub 2019 May 17.

1 Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, MN.

Oligometastatic prostate cancer (OMPC), generally defined by presence of five or fewer metastatic sites on imaging, represents a transitional state between localized and widespread metastatic disease and encompasses a wide spectrum of disease biologies and clinical behaviors. A collaborative effort is ongoing to determine the genomics of OMPC. The prevalence of OMPC varies significantly in the literature and is likely to change further as substantial improvements in imaging improve our ability to reclassify a subset of patients with biochemical recurrence by conventional imaging as OMPC and another subset from OMPC to polymetastatic disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_239041DOI Listing
January 2019
6 Reads

Accuracy of CAPRA-S Score for Predicting Long-Term Biochemical Progression After Radical Prostatectomy.

Clin Genitourin Cancer 2019 06 27;17(3):e645-e649. Epub 2019 Mar 27.

Urology Department, Dr Negrín University Hospital, Las Palmas of Gran Canaria, Las Palmas, Spain.

Background: The Cancer of the Prostate Risk Assessment Postsurgical (CAPRA-S) score is a tool to stratify patients into groups according to their risk for biochemical recurrence after radical prostatectomy. The aim of this study was to assess the accuracy of the CAPRA-S score for predicting biochemical progression at 5 and 10 years in our cohort of patients after radical prostatectomy.

Patients And Methods: Between June 2004 and December 2015, radical prostatectomy was performed as the main treatment option for patients with localized prostate cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2019.03.014DOI Listing
June 2019
1 Read